CN105658818A - 遗传标记物预测醋酸格拉替雷反应 - Google Patents

遗传标记物预测醋酸格拉替雷反应 Download PDF

Info

Publication number
CN105658818A
CN105658818A CN201480058055.6A CN201480058055A CN105658818A CN 105658818 A CN105658818 A CN 105658818A CN 201480058055 A CN201480058055 A CN 201480058055A CN 105658818 A CN105658818 A CN 105658818A
Authority
CN
China
Prior art keywords
snps
genotype
snp
equivalent
allelotrope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480058055.6A
Other languages
English (en)
Chinese (zh)
Inventor
阿米尔·彻利特
迈克尔·海登
里亚特·哈亚丹尼
科林·詹姆斯·道格拉斯·罗斯
艾丽斯·格罗斯曼
大卫·拉德卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CN105658818A publication Critical patent/CN105658818A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201480058055.6A 2013-10-21 2014-10-21 遗传标记物预测醋酸格拉替雷反应 Pending CN105658818A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361893807P 2013-10-21 2013-10-21
US61/893,807 2013-10-21
US201462048127P 2014-09-09 2014-09-09
US62/048,127 2014-09-09
US201462048641P 2014-09-10 2014-09-10
US62/048,641 2014-09-10
PCT/US2014/061647 WO2015061367A1 (en) 2013-10-21 2014-10-21 Genetic markers predictive of response to glatiramer acetate

Publications (1)

Publication Number Publication Date
CN105658818A true CN105658818A (zh) 2016-06-08

Family

ID=52826364

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480058055.6A Pending CN105658818A (zh) 2013-10-21 2014-10-21 遗传标记物预测醋酸格拉替雷反应

Country Status (13)

Country Link
US (2) US9702007B2 (enExample)
EP (1) EP3060681A4 (enExample)
JP (1) JP2016540729A (enExample)
KR (1) KR20160098199A (enExample)
CN (1) CN105658818A (enExample)
AU (1) AU2014340247A1 (enExample)
CA (1) CA2926724A1 (enExample)
EA (1) EA201690759A1 (enExample)
IL (1) IL244783A0 (enExample)
MX (1) MX2016005003A (enExample)
TW (1) TW201610166A (enExample)
UY (1) UY35790A (enExample)
WO (1) WO2015061367A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111088368A (zh) * 2019-12-30 2020-05-01 山西医科大学 一种血液mRNA检测试剂盒及检测方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP2627669B1 (en) 2010-10-11 2016-08-17 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SMT202500136T1 (it) 2016-08-31 2025-05-12 Mapi Pharma Ltd Sistemi a deposito comprendenti glatiramer acetato
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3820573B1 (en) 2018-07-10 2023-08-09 Novartis AG 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
CN102176900A (zh) * 2008-09-17 2011-09-07 克艾思马有限公司 药物组合物和相关的给药方法
CN102458476A (zh) * 2009-06-16 2012-05-16 伊耐特免疫治疗有限公司 用于治疗多发性硬化症的组合物及方法
CN102625657A (zh) * 2009-08-20 2012-08-01 医达研究发展有限公司 低频醋酸格拉替雷疗法
WO2013005683A1 (ja) * 2011-07-01 2013-01-10 日本ゼオン株式会社 二次電池用多孔膜、製造方法、及び用途
CN103169670A (zh) * 2013-03-22 2013-06-26 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE09004306T1 (de) 1998-09-25 2010-12-09 Yeda Research & Development Co., Ltd., Weizmann Institute of Science Mit Copolymer 1 verwandte Polypeptide zur Verwendung als Molekulargewichtsmarker und zur therapeutischen Verwendung
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
WO2000027417A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
CA2400374A1 (en) 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CN1308683C (zh) 2001-12-04 2007-04-04 特瓦制药工业有限公司 测量醋酸格拉默功效的方法
ES2397836T3 (es) 2003-01-21 2013-03-11 Yeda Research And Development Co., Ltd. Copolímero 1 para el tratamiento de enfermedades inflamatorias del intestino
WO2004091573A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2525771A1 (en) 2003-05-14 2004-12-02 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
US20050064483A1 (en) 2003-08-28 2005-03-24 Baylor College Of Medicine Gene expression profiling technology for treatment evaluation of multiple sclerosis
NZ546379A (en) 2003-10-31 2010-04-30 Teva Pharma Nanoparticles for drug delivery
WO2005084377A2 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
SG153871A1 (en) 2004-06-25 2009-07-29 Id Biomedical Corp Quebec Compositions and methods for treating neurological disorders
US20090048181A1 (en) 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
DK1799703T3 (da) 2004-09-09 2010-04-19 Teva Pharma Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
JP2008528589A (ja) 2005-02-02 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 水素化分解を用いてポリペプチド混合物を作成する方法
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
ES2420404T3 (es) 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
US8835111B2 (en) * 2009-03-12 2014-09-16 Brainco Biopharma S.L. Genotyping tool for improving the prognostic and clinical management of MS patients
PT2275086E (pt) 2009-07-15 2012-05-18 Teva Pharma Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2627669B1 (en) 2010-10-11 2016-08-17 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
US8815511B2 (en) 2011-10-10 2014-08-26 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
BR112015014095A2 (pt) 2012-12-21 2017-07-11 Teva Pharma entrega transmucosal de acetato de glatirâmero
KR20150111919A (ko) 2012-12-21 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 경구 경점막 전달
CN105228651A (zh) 2013-01-04 2016-01-06 泰华制药工业有限公司 表征醋酸格拉替雷相关的药品
EP2968559A4 (en) 2013-03-12 2016-11-02 Teva Pharma RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMERACETATE THERAPY
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
CN102176900A (zh) * 2008-09-17 2011-09-07 克艾思马有限公司 药物组合物和相关的给药方法
CN102458476A (zh) * 2009-06-16 2012-05-16 伊耐特免疫治疗有限公司 用于治疗多发性硬化症的组合物及方法
CN102625657A (zh) * 2009-08-20 2012-08-01 医达研究发展有限公司 低频醋酸格拉替雷疗法
WO2013005683A1 (ja) * 2011-07-01 2013-01-10 日本ゼオン株式会社 二次電池用多孔膜、製造方法、及び用途
CN103169670A (zh) * 2013-03-22 2013-06-26 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROSSMAN IRIS ET AL: "pharmacogenetics of glatiraamer acetate therapy for multiple sclerosis receals drug-response markers", 《PHARMACOGENETICS AND GENOMICS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111088368A (zh) * 2019-12-30 2020-05-01 山西医科大学 一种血液mRNA检测试剂盒及检测方法
CN111088368B (zh) * 2019-12-30 2021-04-16 山西医科大学 一种血液mRNA检测试剂盒及检测方法

Also Published As

Publication number Publication date
UY35790A (es) 2015-05-29
JP2016540729A (ja) 2016-12-28
WO2015061367A1 (en) 2015-04-30
KR20160098199A (ko) 2016-08-18
IL244783A0 (en) 2016-04-21
US20180002753A1 (en) 2018-01-04
EP3060681A1 (en) 2016-08-31
TW201610166A (zh) 2016-03-16
US20150110733A1 (en) 2015-04-23
EP3060681A4 (en) 2017-06-07
CA2926724A1 (en) 2015-04-30
AU2014340247A1 (en) 2016-06-02
EA201690759A1 (ru) 2017-01-30
US9702007B2 (en) 2017-07-11
MX2016005003A (es) 2016-08-03

Similar Documents

Publication Publication Date Title
CN105658818A (zh) 遗传标记物预测醋酸格拉替雷反应
US9499868B2 (en) Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
KR20090019848A (ko) 알쯔하이머 병의 진행에 대한 생체마커
JP6496003B2 (ja) Ｆｇｆ−１８化合物に対する応答性を予測するための遺伝子マーカー
JP6272860B2 (ja) 軟骨障害の予後バイオマーカー
US20150278438A1 (en) Genetic predictors of response to treatment with crhr1 antagonists
CN103333952A (zh) 年龄相关的黄斑变性中的遗传多态性
EP3277836B1 (en) Method of treatment using genetic predictors of a response to treatment with ssr-125543
WO2010111080A2 (en) Optimized treatment of schizophrenia
US20160312284A1 (en) Select single nucleotide polymorphisms predictive of response to glatiramer acetate
JP2004508056A (ja) ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
HK1225412A1 (en) Genetic markers predictive of response to glatiramer acetate
JP2008538549A (ja) 高血圧剤としてのアリスキレンの有効性に関するバイオマーカー
CN103261891B (zh) 选择治疗有注意缺陷多动障碍患者的用药方案的方法
Class et al. Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd.
JP2003528593A (ja) ５−ヒドロキシトリプタミン輸送体遺伝子多型
CN103261891A (zh) 选择治疗有注意缺陷多动障碍患者的用药方案的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225412

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160608

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1225412

Country of ref document: HK